AA
ASBPW

AQR Arbitrage’s Aspire Biopharma Warrant ASBPW Stock Holding History

AQR Arbitrage’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-647,633
Closed -$30.8K – 465
2024
Q4 		$30.8K Hold
647,633
– – ﹤0.01% 391
2024
Q3 		$27.4K Hold
647,633
– – ﹤0.01% 401
2024
Q2 		$19.5K Hold
647,633
– – ﹤0.01% 431
2024
Q1 		$19.5K Hold
647,633
– – ﹤0.01% 430
2023
Q4 		$38.9K Hold
647,633
– – ﹤0.01% 416
2023
Q3 		$32.4K Hold
647,633
– – ﹤0.01% 486
2023
Q2 		$32.4K Sell
647,633
-3,612
-0.6% -$133 ﹤0.01% 557
2023
Q1 		$27.2K Sell
651,245
-18,753
-3% -$1.24K ﹤0.01% 690
2022
Q4 		$53.6K Hold
669,998
– – ﹤0.01% 719
2022
Q3 		$74K Hold
669,998
– – ﹤0.01% 822
2022
Q2 		$80K Buy
+669,998
New +$146K ﹤0.01% 843

Other funds holding ASBPW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

AQR Arbitrage's ASBPW Position: Q1 2025 in Review

AQR Arbitrage sold out of Aspire Biopharma Warrant (ASBPW) in Q1 2025, closing a stake of 647,633 shares — an estimated $30.8K sold.

AQR Arbitrage first reported a position in ASBPW in Q2 2022 and held it in 11 quarters. The position peaked at $80K in Q2 2022. 27 funds tracked by Wall St. Rank hold ASBPW as of Q1 2025.

  • AQR Arbitrage reported no remaining Aspire Biopharma Warrant position as of Q1 2025 after selling out during the quarter.
  • AQR Arbitrage sold 647,633 Aspire Biopharma Warrant shares in Q1 2025, an estimated $30.8K.
  • AQR Arbitrage first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 11 quarters.
  • AQR Arbitrage's Aspire Biopharma Warrant position peaked at $80K in Q2 2022.
  • 27 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q1 2025.

Based on AQR Arbitrage's 13F filing for Q1 2025, filed 15 May 2025.